Please ensure Javascript is enabled for purposes of website accessibility

4 More Healthcare Earnings Reports to Watch This Week

By Cory Renauer – Updated Apr 30, 2019 at 9:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.

It's that time of the season when healthcare companies begin peppering investors with a flurry of earnings reports. If you still aren't sure which ones to watch, don't sweat it.

At least four healthcare companies still scheduled to report this week deserve your attention. Read on to find out why.

Company (Symbol) Scheduled Date  1-Year Stock Performance
Amarin (AMRN -4.27%) Wednesday, May 1 577%
Exact Sciences (EXAS -2.09%) Tuesday, April 30 89%
Merck & Co. (MRK 0.87%) Tuesday, April 30 29%
Amgen (AMGN 0.16%) Tuesday, April 30 2%

Data source: Company releases and Yahoo! Finance.

1. Amarin: Can Vascepa sales keep accelerating?

Last year, Amarin blew the lid off its stock price with better-than-expected results from the Reduce-It trial with its special fish oil pill, Vascepa. This study enrolled people already using statins to lower their cholesterol if they also have dangerously high triglycerides, a description that fits an estimated 9.5 million Americans.

Adding a daily dose of Vascepa to regular statin therapy reduced the risk of a major adverse cardiovascular event (MACE) by 25% compared with a placebo, and sales have been accelerating ever since. Vascepa revenue rose 44% in the fourth quarter to an annualized $309 million. 

When Amarin reports first-quarter results on Wednesday morning, investors will be looking for a continuation of unexpected early revenue growth in response to the results. Three months ago, the company expected Vascepa sales to rise by at least 50% to around $350 million in 2019, and an upward revision could be in the cards. 

Amarin submitted its application to add a new indication to Vascepa's prescribing label about a month ago, and the Food and Drug Administration still has another month to officially begin a review that will probably last until January. An eventual green light that allows Amarin to officially market Vascepa as a treatment to lower MACE risk is expected to drive revenue from $229 million in 2018 to $1.9 billion by 2024.

Happy guy in a lab coat using a pipette.

Image source: Getty Images.

2. Exact Sciences: Reaching the other 95.9%

When Exact Sciences reports first-quarter earnings on Tuesday afternoon, investors will be looking for signs that Cologuard can continue growing its share of eligible patients from 4.1% at the end of 2018 to a double-digit percentage soon. The company thinks there are around 85 million Americans between 50 and 85 who should get screened every three years. Thanks to the Affordable Care Act, insurers can't charge their customers for recommended Cologuard screenings.

The company completed 934,000 tests last year, which was 66% more than a year earlier, thanks to bombarding Americans with advertisements. Last August, the company hired Pfizer (PFE 0.41%) to help promote Cologuard, and sales appear to have accelerated in the fourth quarter of 2018. If it still looks like this marketing collaboration will help Exact Sciences reach a much larger share of eligible patients, the stock could soar.

3. Merck: Can Keytruda become the world's top-selling drug?

In 2018, Merck's lead drug, Keytruda, earned approval to treat six new indications, including patients newly diagnosed with the most common forms of lung cancer. Investors will be looking for signs Keytruda can become the world's top-selling drug in 2025, when Merck reports first-quarter earnings on Tuesday morning.

Keytruda sales rose 66% in the fourth quarter to an annualized $8 billion. With a leading share of the important lung cancer population, there's a pretty good chance Keytruda can continue climbing at its recent pace for at least another year or two.

Scientist in the laboratory looking at charts and graphs.

Image source: Getty Images.

4. Amgen: Still in the lead?

Last year, Amgen was the first of three companies to launch a new type of migraine prevention treatment, Aimovig. There are millions of Americans who could benefit from fewer migraine days each month, making Aimovig a huge potential growth driver. Investors will be even more interested in Aimovig now that there's a chance Amgen can wiggle out of a collaboration deal with Novartis.

By the end of 2018, over 150,000 patients tried Aimovig, which worked out to a majority of new migraine drug prescriptions filled last year. When Amgen reports first-quarter earnings on Tuesday afternoon, investors will be looking for signs that Aimovig has maintained its leading share of the migraine space.

Most combustible?

Aimovig could become an important growth driver for Amgen, but the big biotech could probably continue pushing the needle forward if it fizzles out. The rest of these healthcare stocks, though, are extremely dependent on their lead products. 

It was unintentional, but I've listed the stocks in order of combustibility, with Amarin as most likely to go screaming higher, or lower. Keep that in mind if you're going to dig further to see if any of these stocks are worthy of your portfolio.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
$108.44 (0.87%) $0.94
Amarin Stock Quote
$1.12 (-4.27%) $0.05
Amgen Stock Quote
$284.19 (0.16%) $0.45
Exact Sciences Stock Quote
Exact Sciences
$41.76 (-2.09%) $0.89
Pfizer Stock Quote
$49.41 (0.41%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.